Widely recognised kidney cancer targeted agents fall into two categories, TKI and mTOR inhibitors, acting through VHL/HIF/VEGF and PI3K/AKT/mTOR signalling pathways respectively (4). This evidence concerns the gene AKT1 and kidney cancer.